Study Links Pharmaceutical Patent Practices to Higher Drug Costs

New research published in JAMA indicates that pharmaceutical companies use "patent thickets"—multiple non-primary patents—to extend market exclusivity for brand-name drugs. This strategy delays generic competition by an average of 6.1 years, contributing significantly to increased medication costs for consumers. The findings highlight a systemic issue impacting healthcare affordability and access to more economical drug options.